

The Newest Big Pharma Scam Exposed

By [Thom Hartmann](#)

Region: [USA](#)

Global Research, October 11, 2021

Theme: [Intelligence](#), [Science and Medicine](#)

[The Hartmann Report](#) 8 October 2021

All Global Research articles can be read in 51 languages by activating the “Translate Website” drop down menu on the top banner of our home page (Desktop version).

Visit and follow us on Instagram at [@crg_globalresearch](#).

Big Pharma’s obscenely-priced drugs developed w/tax dollars will continue to drain working people of income, savings, and - ultimately - their health until America recognizes healthcare as a right

[Molnupiravir](#) is the new pill that’s been all over the news recently because it can cut hospitalizations and deaths of unvaccinated Covid-infected people by as much as half and doesn’t require folks to go to the hospital or an infusion center, like the [monoclonal antibody](#) treatment. Just take four pills every day for five days and you’re good.

It was [originally developed by Emory University to treat horses infected with Venezuelan equine encephalitis](#) with a \$10 million grant from the Department of Defense and \$19 million from the National Institutes of Health. In other words, [its invention was paid for with your tax dollars](#).

Emory University passed along the patent on molnupiravir to a small company, Ridgeback Biotherapeutics, which in turn passed it along to the pharmaceutical giant Merck.

Manufacturing cost for molnupiravir, [according to a report from researchers with the Harvard School of Public Health](#), is around \$17.74 for a 5-day course of treatment.

Merck just signed a contract with the federal government to sell 1.7 million treatment courses for the government to distribute to infected people for ... wait for it ... \$712.00 each.

This price-gouging hustle was both made possible — and, ironically, perhaps made illegal — by a piece of legislation passed back in 1980 that gave universities the ability to sell patents to inventions funded with federal money to non-profit organizations and small businesses...but not to major corporations. Since then, small businesses like Ridgeback have served as middlemen handing off profitable pharmaceuticals developed with our tax dollars to giant corporations like Merck.

Back in 1980, **Senators Birch Bayh and Bob Dole** got passed, over then-President Jimmy

Carter's objections ([it was first shot down and only passed during the lame duck session by being attached to must-pass legislation](#)) the Patent and Trademark Law Amendments Act, now usually referred to as Bayh-Dole. Industry and trade groups loudly sing its praises, although [they're worried about a provision of the law](#)(that's apparently [never been used](#)) called "March-in Authority."

"March-in" allows the federal government to say, essentially, "We paid to develop this drug so you have to sell it to us at a reasonable price; we think you're ripping us off right now so we're going to claw back that patent from you and assign it to somebody else."

As professors [Peter Arno and Michael Davis wrote in *The Washington Post*](#):

"Bayh-Dole is a provision of U.S. patent law that states that practically any new drug invented wholly or in part with federal funds will be made available to the public at a reasonable price. If it is not, then the government can insist that the drug be licensed to more reasonable manufacturers, and, if refused, license it to third parties that will make the drug available at a reasonable cost."

So Big Pharma called up their lobbyists and Trump's billionaire Secretary of Commerce, Wilbur Ross (who [Forbes magazine said](#) "could rank among the biggest gifters in American history"), jumped into the act.

In the last year of the Trump administration, Ross's Commerce Department began the process of stripping "March-in" out of Bayh-Dole so Big Pharma could rip off the US government as much as it wanted, whenever it wanted. In the [Federal Register it was phrased this way](#):

"(7) Clarify § 401.6 to include a provision that march-in rights shall not be exercised by an agency exclusively on the basis of business decisions of a contractor regarding the pricing of commercial goods and services arising from the practical application of the invention."

The issue is [still live before the Biden Commerce Department](#), so watch this space.

Meanwhile, big Pharma is buying off members of Congress to encourage an end to "March-in" and block any efforts to regulate the cost of drugs or let Medicare negotiate prices.

That little provision draining billions every month from the Medicare fund, along with the [privatization of Medicare through the Medicare Advantage Scam](#), came to us courtesy of the George W. Bush administration, after [Bush tried and failed to entirely privatize both Social Security and Medicare](#).

Most recently, when legislation was before the House of Representatives to allow Medicare to radically cut their expenses by negotiating drug prices (just like the VA and major insurers do), it was shot down in committee by every single Republican [joined by three paid-off "Problem Solver" Democrats](#): Scott [Peters of California](#), Kathleen [Rice of New York](#) and [Oregon's Kurt Schrader](#).

Drugs have become a huge rip-off of the American people, making Big Pharma's executives and shareholders fabulously rich and generating a huge pot of money that 5 conservatives on the Supreme Court ruled, [in *Citizens United*](#), drug companies are welcome to use to

corrupt politicians. [A recent study found](#):

- “For 17 of the 20 top-selling drugs worldwide, drugmakers made more money from U.S. sales than from sales to all other countries in the rest of the world *combined*.”
- “For 11 of the 20 top-selling drugs worldwide, U.S. sales revenue was double or more the revenue for sales in the rest of the world.”

We are, uniquely in the world, being robbed.

As [Congressman Ro Khanna told *The Daily Poster*](#), “The pharmaceutical lobby is very savvy. They pick the one or two people they need to block things, on the relevant committees or at the relevant time.” And this time, they’ve “picked” Senator Kyrsten Sinema, [pouring a flood of cash into her pockets](#) so she will block any efforts to control drug prices in Biden’s reconciliation *Build Back Better* legislation.

As I lay out in my new book, [The Hidden History of American Healthcare: Why Sickness Bankrupts You and Makes Others Insanely Rich](#), until America joins the rest of the developed world in considering healthcare a *right* rather than a *privilege*, these [giant, multi-billion-dollar-a-year scams like Medicare Advantage](#) and obscenely-priced drugs developed with *our own tax dollars* will continue to drain working people of their income, savings, and — ultimately — their health.

*

Note to readers: Please click the share buttons above or below. Follow us on Instagram, @crg_globalresearch. Forward this article to your email lists. Crosspost on your blog site, internet forums. etc.

Featured image is by [Septimiu Balica](#) from [Pixabay](#)

The original source of this article is [The Hartmann Report](#)
Copyright © [Thom Hartmann](#), [The Hartmann Report](#), 2021

[Comment on Global Research Articles on our Facebook page](#)

[Become a Member of Global Research](#)

Articles by: [Thom Hartmann](#)

Disclaimer: The contents of this article are of sole responsibility of the author(s). The Centre for Research on Globalization will not be responsible for any inaccurate or incorrect statement in this article. The Centre of Research on Globalization grants permission to cross-post Global Research articles on community internet sites as long the source and copyright are acknowledged together with a hyperlink to the original Global Research article. For publication of Global Research articles in print or other forms including commercial internet sites, contact: publications@globalresearch.ca

www.globalresearch.ca contains copyrighted material the use of which has not always been specifically authorized by the copyright owner. We are making such material available to our readers under the provisions of "fair use" in an effort to advance a better understanding of political, economic and social issues. The material on this site is distributed without profit to those who have expressed a prior interest in receiving it for research and educational purposes. If you wish to use copyrighted

material for purposes other than "fair use" you must request permission from the copyright owner.

For media inquiries: publications@globalresearch.ca